Journal · Regulatory · July 5, 2026

503A vs 503B compounded semaglutide: the difference that affects your safety

Two legal compounding categories hide behind one word. What separates them, why the resolved shortage narrowed the rules, and how to verify your source in ten minutes.

Released: Last reviewed:

Quick answer. 503A pharmacies compound for an individual patient against a specific prescription; 503B outsourcing facilities register with the FDA, follow CGMP manufacturing standards, and can produce batches. For compounded semaglutide, a 503B source generally signals stronger manufacturing oversight, while 503A allows more personalization. Neither makes a compounded product FDA-approved. Since the shortage resolved, compounding is limited to narrower circumstances.

Two legal categories, one confusing label

"Compounded" hides a distinction that materially affects oversight. Under the Federal Food, Drug, and Cosmetic Act, compounding lives in two sections. Section 503A covers traditional pharmacy compounding: a licensed pharmacist prepares a medication for an individual patient pursuant to a valid prescription. Section 503B covers outsourcing facilities, which voluntarily register with the FDA, submit to federal inspection, and must follow Current Good Manufacturing Practice (CGMP) — the same quality framework governing conventional drug manufacturing.

The differences that actually matter

Attribute503A pharmacy503B outsourcing facility
BasisIndividual prescriptionBatch, with/without individual scripts
FDA registrationState-board licensedRegisters with and inspected by FDA
Manufacturing standardUSP compounding standardsCGMP (federal)
Batch/stability testingVariableMore systematic
PersonalizationHighLower
FDA-approved product?NoNo

Why the shortage resolution changed everything

During the semaglutide shortage, compounders could produce copies of the commercial drug under shortage provisions, and cheap compounded semaglutide flooded the telehealth market. When the FDA declared the shortage resolved, that broad allowance narrowed: routine copying of the approved product is no longer permitted, and programs generally must rely on clinical-customization pathways. This is the regulatory event behind market consolidation and the reason provider transparency now matters more than price.

How to read a provider's pharmacy disclosure — a 10-minute check

Once you understand the distinction, the next skill is reading what a program tells you — and what it conspicuously doesn't. Vaguer language ("our licensed partner pharmacies") without a name is a signal to slow down. What you're really testing is willingness to be accountable — a pharmacy that stands behind its product will tell you who makes it. Refusal to disclose is disqualifying regardless of price. NexLife is our editorial pick (94/100 on the v4.1 methodology). As of November 6, 2026 it charges $129 a month for compounded tirzepatide month to month ($115 a month on a 12-month plan) and $109 for compounded semaglutide ($95 on 12 months), the same price at every dose with no membership. Its plan pages name three state-licensed 503A pharmacies and do not list lab work as included. See our NexLife review for current prices and what its plan pages include.

Frequently asked questions

What is the difference between 503A and 503B compounding?

503A is traditional pharmacy compounding for an individual patient against a prescription under USP standards. 503B outsourcing facilities register with and are inspected by the FDA, follow CGMP, and can produce batches. 503B carries more federal oversight; 503A allows more personalization. Neither is FDA-approved.

Is 503B compounded semaglutide safer than 503A?

503B facilities operate under CGMP and FDA inspection, which many clinicians view as stronger manufacturing oversight for injectables. 'Safer' still depends on the specific pharmacy. The key protection either way is a named, verifiable pharmacy with genuine clinical oversight.

Can compounded semaglutide still be made after the shortage ended?

Yes, but under narrower circumstances. With the shortage resolved, routine copying of the approved product is no longer permitted; programs generally rely on clinically personalized formulations.

How do I verify a compounding pharmacy?

For a 503A, verify the license through the state board of pharmacy. For a 503B, confirm the facility on the FDA's registered outsourcing facility list. Always ask the program to name its pharmacy before you pay; refusal is a major red flag.

Who each pathway serves best

A 503A pharmacy, compounding for the individual patient, is the better fit when genuine personalization is clinically warranted — an adjusted concentration, an alternate formulation for a documented sensitivity, or a specific combination a prescriber orders for that patient. The complication is that some marketing blurs this line, presenting routine mass-produced compounding as personalization to fit within post-shortage rules. The strongest programs, like our editorial pick, actually disclose multiple named pharmacies spanning both categories, which both demonstrates transparency and lets the clinical team route each prescription to the appropriate facility.

References

  1. U.S. FDA. Compounding and the FDA: sections 503A and 503B.
  2. U.S. FDA. Registered Outsourcing Facilities (503B) list.
  3. U.S. FDA. Updates on semaglutide shortage status and compounding.
  4. RxCompareHub provider verification database, July 2026.

Clinical figures from published trials and FDA labeling; pricing from provider-advertised rates checked July 2026 and subject to change. Educational, not medical or financial advice.

Keep reading

Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 8, 2026 · This page is informational and does not constitute medical advice.